Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2003 | 12-2002 | 09-2002 | 06-2002 | 03-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,680 | -22,240 | -24,270 | -16,050 | -7,530 |
| Depreciation Amortization | 1,030 | 4,180 | 3,110 | 2,030 | 960 |
| Other Working Capital | -350 | 2,340 | 1,830 | 1,590 | 210 |
| Other Operating Activity | 3,040 | -12,730 | -1,340 | -1,120 | -560 |
| Operating Cash Flow | $-6,960 | $-28,450 | $-20,670 | $-13,550 | $-6,920 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -430 | -130 | -130 | -950 | -60 |
| Other Investing Activity | 9,880 | 26,650 | 22,540 | 15,130 | 3,960 |
| Investing Cash Flow | $9,450 | $26,520 | $22,410 | $14,180 | $3,900 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | -240 | 350 | 810 | -360 | -240 |
| Financing Cash Flow | $-240 | $350 | $810 | $-360 | $-240 |
| Exchange Rate Effect | 80 | 470 | 320 | 360 | -70 |
| Beginning Cash Position | 9,350 | 10,450 | 10,450 | 10,450 | 10,450 |
| End Cash Position | 11,680 | 9,350 | 13,340 | 11,080 | 7,120 |
| Net Cash Flow | $2,330 | $-1,100 | $2,880 | $630 | $-3,320 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,960 | -28,450 | -20,670 | -13,550 | -6,920 |
| Free Cash Flow | -6,960 | -28,450 | -20,670 | -13,550 | -6,920 |